论文部分内容阅读
目的:观察和评价长春瑞滨联合表柔比星治疗晚期乳腺癌的疗效和毒副反应。方法:24例晚期乳腺癌患者接受化疗:长春瑞滨25 mg/m2,第1天,第8天;表阿霉素35 mg/m2,第2天,第9天;28 d重复,治疗两个周期以上进行疗效评价。结果:总有效率为66.7 %,完全缓解率为8.3 %。其中软组织部位有效率为71.4 %,淋巴结为90.0 %,肝脏为60.0 %,胸壁为50.0 %,骨骼为40.0 %,肺脏为33.3 %。毒副作用主要为白细胞减少和恶心呕吐。结论:长春瑞滨联合表柔比星治疗晚期乳腺癌有较高的疗效,治疗时毒副反应可以耐受。
Objective: To observe and evaluate the efficacy and side effects of vinorelbine combined with epirubicin in the treatment of advanced breast cancer. Methods: Twenty-four patients with advanced breast cancer received chemotherapy: vinorelbine 25 mg / m2 on day 1 and day 8; epirubicin 35 mg / m2 on day 2 and day 9; A cycle of efficacy evaluation. Results: The total effective rate was 66.7% and the complete response rate was 8.3%. The effective rate of soft tissue was 71.4%, lymph node 90.0%, liver 60.0%, chest wall 50.0%, bone 40.0% and lung 33.3%. The main side effects of leukopenia and nausea and vomiting. Conclusion: Vinorelbine combined with epirubicin in the treatment of advanced breast cancer has a higher efficacy, the treatment of toxic and side effects can be tolerated.